Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 9/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204984 | 1.00 | PTGDR2 (0.38) | PTGDR2PTGDRCYP2C9AGTR2TBXA2R | |
| SCHEMBL3085509 | 0.95 | AGTR2 (0.39) | PTGDR2PTGDRCYP2C9AGTR2HSD11B1 | |
| SCHEMBL3099698 | 0.94 | PTGDR2 (0.34) | PTGDR2PTGDRCYP2C9AGTR2TBXA2R | |
| SCHEMBL3084609 | 0.91 | PTGDR2 (0.37) | PTGDR2PTGDRCYP2C9AGTR2HSD11B1 | |
| SCHEMBL3090539 | 0.89 | PTGDR2 (0.38) | PTGDR2PTGDRCYP2C9TBXA2RHSD11B1 | |
| SCHEMBL3078753 | 0.87 | PTGDR2 (0.53) | PTGDR2PTGDRCYP2C9AGTR2TBXA2R | |
| SCHEMBL3220734 | 0.86 | PTGDR2 (0.39) | PTGDR2PTGDRCYP2C9AGTR2TBXA2R | |
| SCHEMBL3091564 | 0.84 | PTGDR2 (0.39) | PTGDR2PTGDRCYP2C9TBXA2RCYP3A4 | |
| SCHEMBL3090471 | 0.84 | PTGDR2 (0.39) | PTGDR2PTGDRCYP2C9TBXA2RCYP3A4 | |
| SCHEMBL3083460 | 0.84 | PTGDR2 (0.39) | PTGDR2PTGDRCYP2C9TBXA2RCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023864-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | claimed |
| EP-2492267-B1 | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient | MERCK SHARP & DOHME (US) | 2014-11-26 | — | — | EP | claimed |
| EP-2401269-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | claimed |
| US-8394819-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | claimed |
| EP-2492267-A1 | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | claimed |
| US-20100234415-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-16 | — | — | US | claimed |
| EP-2492267-B1 | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient | MERCK SHARP & DOHME (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2401269-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-8394819-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2492267-A1 | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20100234415-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234415-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | PTGDR2 2/4885PTGDR 3/4885CYP2C9 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.